The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 8.50
Ask: 10.00
Change: 0.00 (0.00%)
Spread: 1.50 (17.647%)
Open: 9.25
High: 9.25
Low: 9.25
Prev. Close: 9.25
NBB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options to Directors and Employees

18 Mar 2022 07:00

RNS Number : 1641F
Norman Broadbent PLC
18 March 2022
 

Norman Broadbent plc

("Norman Broadbent", "NBB" or the "Group")

Grant of Options to Directors and Employees

Norman Broadbent (AIM: NBB), a leading London quoted Executive Search and Interim Management firm offering a diversified portfolio of integrated Leadership Acquisition & Advisory Services, announces that on 17 March 2022, the Group's Board of Directors agreed to a grant of 12,148,151 options over ordinary shares ("Options") to the Company's Executive Directors and certain employees under the Company's Enterprise Management Incentive Option Scheme 2022 (the "Scheme"). The options are exercisable at 0p (zero pence) per ordinary share.

The Options granted under the Scheme are subject to various conditions. They vest over a 4-year period (25 per cent. per year) starting 12 months after the date of the grant. No exercise can be made until at least 24 months from the date of the grant. Once vested, the Options can be exercised within 7 years of the grant date subject to two sets of performance criteria:

· 50 per cent. of the vested Options are exercisable on a scaled level following the share price of the Company achieving an average price of between 10p and 19p over any three-month period prior to 30 June 2026; and

 

· The remaining 50 per cent. of vested Options are exercisable on a scaled level following the achievement of audited EBITDA in the range of greater than £500,000 to £1,250,000 for any financial year of the Company from date of grant to 31 December 2025.

The following table sets out the details of the Options that have been granted to the Executive Directors:

Director

Share Price Vesting Options

EBITDA Vesting Options

Total Number of Options Granted

Total Number of Options Held

Percentage of Existing Issued Shares Under Option

Percentage of the Fully Diluted Share Capital*

Kevin Davidson

975,000

975,000

1,950,000

1,950,000

3.2%

2.7%

Peter Searle

500,000

500,000

1,000,000

1,000,000

1.6%

1.4%

Steve Smith

725,000

725,000

1,450,000

1,450,000

2.4%

2.0%

Total

2,200,000

2,200,000

4,400,000

4,400,000

7.2%

6.1%

 

*assuming that no further ordinary shares are issued by the Company between the date of this announcement and the exercise of the options.

Following the issue, options outstanding of 9,950,000 representing 16.4 per cent. of the current shares in issue. The Company has the ability to issue an additional 2,198,151 options under the scheme to a maximum of 20 per cent. of issued share capital. At the date of this announcement, the Company has 60,740,757 ordinary voting shares in issue.

Related Party Transactions

As Kevin Davidson, Peter Searle and Steve Smith, who are receiving options, are Directors of the Company, the grant of the aggregate number of Options to them constitutes a related party transaction as defined by the AIM Rules. Accordingly, the Independent Directors being Fiona McAnena, Angela Hickmore and Devyani Vaishampayan having consulted with WH Ireland Limited, the Company's Nominated Adviser, consider that the terms of this option grant are fair and reasonable insofar as shareholders are concerned.

The FCA notification, made in accordance with the requirements of the UK Market Abuse Regulation is appended further below.

Peter Searle, Executive Chairman of Norman Broadbent, commented:

"This options grant is a great opportunity for key team members across the Group to become beneficiaries of the future success of Norman Broadbent and, if the ambitious targets are achieved, will result in significant returns to all stakeholders. The Company's major shareholders are supportive of this grant and feel that this creates appropriate incentivisation to now align all parties in driving profitability and value in the business over the coming years."

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

PDMRs:

Kevin Davidson

Chief Executive Officer

Peter Searle

Executive Chairman

Steve Smith

Group CFO & COO

 

2

Reason for the notification

a)

Position/status

See 1a) above

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Norman Broadbent Plc

b)

LEI

213800E5YN5TA934XA23

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Options over ordinary shares of £0.01 each in Norman Broadbent Plc

Identification code (ISIN) for Norman Broadbent Plc ordinary shares: GB00B3VF4Y66

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Name

Price(s)

Volume(s)

Kevin Davidson

nil

1,950,000

Peter Searle

nil

1,000,000

Steve Smith

nil

1,450,000

 

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transactions

Options put in place as of 17 March 2022

f)

Place of the transaction

Outside a trading venue

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For further information, please contact:

Norman Broadbent plc +44 (0) 20 7484 0000

Kevin Davidson

Peter Searle

Steve Smith

WH Ireland Limited +44 (0) 20 7220 1666

Jessica Cave

Darshan Patel

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFAFEWEESEID
Date   Source Headline
25th Apr 20247:00 amRNSQ1 2024 Trading Update
24th Apr 20247:00 amRNSSmall Cap Awards nomination
15th Apr 20243:18 pmRNSNotification of major holdings
8th Apr 202412:11 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20244:01 pmRNSNotification of major holdings
28th Mar 20247:00 amRNSPosting of ARA & Notice of AGM
27th Mar 20247:00 amRNSFinal Results
26th Mar 20244:07 pmRNSNotification of major holdings
20th Mar 20241:36 pmRNSNotice of Results & Investor Presentation
18th Mar 20244:33 pmRNSNotification of major holdings
18th Mar 20244:04 pmRNSNotification of major holdings
12th Mar 20243:33 pmRNSAIM Rule 17 Schedule Two (g) Update
22nd Jan 20245:32 pmRNSNotification of Major Holdings
16th Jan 20247:00 amRNSTrading Update
21st Nov 202310:06 amRNSNotification of Major Holdings
20th Nov 202310:45 amRNSDirector/PDMR shareholding
15th Nov 20239:54 amRNSNotification of Major Holdings
15th Nov 20239:43 amRNSNotification of Major Holdings
10th Nov 20237:00 amRNSDirector/PCA Dealing
9th Nov 20232:25 pmRNSDirector/PDMR Shareholding
2nd Nov 20238:43 amRNSConversion Of Outstanding Convertible Loan Notes
12th Oct 20237:00 amRNSQ3 2023 Trading Update
10th Oct 202311:03 amRNSNotification of Major Holdings
9th Oct 20237:00 amRNSSurrender and Granting of Options
28th Jul 20237:00 amRNSGrant of Options
24th Jul 20237:00 amRNSInterim Results
11th Jul 20237:00 amRNSH1 2023 Trading Update
30th Jun 20237:00 amRNSSAYE Option Plan & Director Holding
29th Jun 20234:28 pmRNSResult of AGM
5th Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 20237:00 amRNSDirectorate changes
31st May 20237:00 amRNSFinal Results
22nd May 20237:00 amRNSQ1 2023 Trading Update
19th May 202312:55 pmRNSPartial Repayment of Convertible Loan Note
24th Jan 20237:00 amRNSTrading Update
10th Jan 20237:00 amRNSDirectorate Change
17th Nov 20224:42 pmRNSTR-1: Notification of major holdings
14th Nov 20227:00 amRNSIssue of Equity
1st Nov 20227:00 amRNSUpdate and Change of Board role
10th Oct 20225:30 pmRNSTR-1: Notification of major holdings
31st Aug 20227:00 amRNSDirector Share Purchase
23rd Aug 20227:00 amRNSDirectorate Change
16th Aug 20227:00 amRNSInterim Results
29th Jul 20227:00 amRNSChange of Adviser
20th Jul 20224:08 pmRNSDirector/PDMR Dealing
11th Jul 20227:00 amRNSTrading Update
29th Jun 20223:15 pmRNSDirector/PDMR Shareholding
23rd Jun 202212:14 pmRNSResult of AGM
7th Jun 20228:59 amRNSHolding(s) in Company
25th May 20227:00 amRNSFinal 2021 Results and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.